Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026)
Kymera Therapeutics (KYMR) reported EBITDA Margin of 218.91% for Q1 2026, up 7138.0% year-over-year from 3.02% in Q1 2025, and up 92.75% quarter-over-quarter from 3020.28% in Q4 2025.
Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EBITDA Margin data on file, last reported at 218.91% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 218.91%, up 7138.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 619.99% (down 21384.0% YoY), and the FY2025 annual result was 785.66%, down 30812.0% from the prior year.
- EBITDA Margin climbed to 218.91% in Q1 2026 per KYMR's latest filing, from 3020.28% in the prior quarter.
- Over five years, EBITDA Margin peaked at 26.04% in Q4 2023 and troughed at 3020.28% in Q4 2025.
- A 5-year average of 797.2% and a median of 412.18% in 2023 frame the typical range for EBITDA Margin.
- On a YoY basis, EBITDA Margin climbed as much as 19364 bps in 2025 and fell as far as 201720 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 210.06% in 2022, then soared by 88 bps to 26.04% in 2023, then sank by 3752 bps to 1003.08% in 2024, then slumped by 201 bps to 3020.28% in 2025, then jumped by 93 bps to 218.91% in 2026.
- Business Quant data shows KYMR's EBITDA Margin at 218.91% in Q1 2026, 3020.28% in Q4 2025, and 2928.84% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -218.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -218.91% |
| Dec 31, 2025 | -3,020.28% |
| Sep 30, 2025 | -2,928.84% |
| Jun 30, 2025 | -664.67% |
| Mar 31, 2025 | -290.29% |
| Dec 31, 2024 | -1,003.08% |
| Sep 30, 2024 | -1,562.60% |
| Jun 30, 2024 | -165.24% |
| Mar 31, 2024 | -483.93% |
| Dec 31, 2023 | -26.04% |
| Sep 30, 2023 | -1,093.10% |
| Jun 30, 2023 | -238.58% |
| Mar 31, 2023 | -412.18% |
| Dec 31, 2022 | -210.06% |
| Sep 30, 2022 | -470.44% |
| Jun 30, 2022 | -356.30% |
| Mar 31, 2022 | -407.82% |
| Dec 31, 2021 | -225.30% |
| Sep 30, 2021 | -141.27% |
| Jun 30, 2021 | -133.08% |